Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SORL1-blocking antibody
- Development stage
- Preclinical
- Lead developer
- Yale University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
SORL1-blocking antibody is an experimental monoclonal antibody that targets Sortilin-related receptor 1 (SORL1), a protein involved in endosomal trafficking and recycling. In ovarian cancer, SORL1 is found to regulate the recycling of integrins (specifically α3/β1) and growth factor receptors (EGFR, FGFR4) to the cell surface, which facilitates cancer cell adhesion, invasion, and mesothelial clearance—key steps in peritoneal dissemination. By inhibiting SORL1, the antibody disrupts these trafficking pathways, leading to the sequestration of integrins in intracellular compartments and reducing the metastatic potential of ovarian cancer cells. This therapeutic strategy is being explored to prevent or treat recurrent ovarian cancer metastasis.
- Other names
- anti-SORL1 antibodyanti-SORL-1 antibodyanti-SORL 1 antibody
02
Targets
SORL1 (Sortilin-related receptor 1)
Beyond the preview
Go deeper on SORL1-blocking antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SORL1-blocking antibody.